— For decades, carbohydrates have been a tough nut to crack in biosynthesis—their structures are just incredibly complex. But that’s finally starting to change. With biopharmaceutical and functional nutrition food companies in urgent need of high-purity glycans, synthetic glycobiology is quickly transitioning from academic theory to real-world production. This approach lies at the heart of what is now known as synthetic glycobiology.
CD BioGlyco has charted a different course in this field. Moving beyond conventional platforms that rely on traditional chemical synthesis or inefficient natural extraction, they have built a system designed to actively engineer cellular behavior. The core idea is a fundamental shift in mindset: instead of passively awaiting nature’s output, they proactively rewrite the cell’s metabolic “source code.
The Leap from “Natural Extraction” to “Molecular Assembly”
Structural isomers and intricate branching have always made mass-producing sugars difficult. CD BioGlyco’s GlycoChas™ Cells platform changes that. It uses a “Design-Build-Test-Learn” cycle to turn microorganisms—like E. coli or yeast—into highly efficient “sugar factories.”
Using CRISPR, the team goes in and systematically tweaks the host cells in a few key ways:
First, they shut down the cell’s own metabolic pathways that waste the raw materials we need.
Next, they reroute the cell’s energy flow, forcing it to focus on building the specific target glycan.
The goal throughout is to make sure the final product is structurally identical to what you’d find in nature.
This shift—from passively using what cells make to actively programming them—makes it possible to produce bio-equivalent glycoconjugates at scale, all in a controlled setting.
This approach is already gaining traction in high-value industries. In pharma, for instance, it’s being used to tweak the sugar structures on antibodies, which can dramatically boost how well a drug works. It also opens the door to better carbohydrate-based vaccines. Over in human nutrition, the platform offers a way to produce human milk oligosaccharides (like 2′-FL) at scale—without needing to source them from breast milk. In a recent pilot project with a European nutrition company, the platform successfully cut development time for a new HMO-producing strain by nearly 40%.
CD BioGlyco helps research institutions skip the trial-and-error phase in carbohydrate R&D—by offering end-to-end services that cover everything from pathway design to strain optimization to large-scale fermentation. That means faster timelines for getting new drugs to market, and lower costs for producing complex glycans.
Vision: Bridging Synthetic Biology and Glycoscience
Looking ahead, this type of platform will become a critical piece of the puzzle in developing the “customized” glycoconjugates needed for personalized medicine. By integrating synthetic glycobiology into industrial application， CD BioGlyco’s rapidly expanding library of engineered cell lines is thereby becoming a solid bridge—connecting cutting-edge synthetic biology theory with real-world industrial application.
CD BioGlyco offers end-to-end glycobiology services, from analyzing and synthesizing glycans to modifying them. Their synthetic biology platform is built to help clients in pharma, food, and cosmetics get access to advanced biomanufacturing that actually works at scale.
Contact Info:
Name: Anna Bryan
Email: Send Email
Organization: CD BioGlyco
Website: https://www.bioglyco.com/
Release ID: 89186842
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
